logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

WCLC 2019 – Looking at first-line immunotherapy combinations in special populations with advanced Non-Small Cell Lung Cancer

Checkmate 817 trial showed that patients with comorbidities and impaired performance status could benefit from first-line treatment with nivolumab+ipilimumab